[Pharmacological characteristics and clinical study results of danicopan (Voydeya^? tablets)].

已完结 20 由 musu 发布于 2025/7/25 15:51:34

DOI:10.1254/fpj.25017
作者：Hideo Hayashi
文献类型：期刊论文
补充材料：只需要正文

其它数据库

Abstract：Danicopan (brand name: Voydeya® tablets) is a new oral small molecule complement factor D inhibitor that was approved in Japan in January 2024 for paroxysmal nocturnal hemoglobinuria (PNH).

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:American Institute of Physics (AIP)Electrical control of ON–OFF magnetism and exchange bias via reversible ionic motion

[Pharmacological characteristics and clinical study results of danicopan (Voydeya? tablets)].

[Pharmacological characteristics and clinical study results of danicopan (Voydeya^? tablets)].